Roche`s Alecensa Granted Accelerated FDA Approval in Lung Cancer
This is a new treatment for a type of lung cancer that has spread - including to the brain. 60% of patients with brain mets saw shrinkage of the tumor. 18% had a complete response. On average, these responses lasted 9 months. This is proof that the drug crossed the blood brain barrier. It might be worth considering using for any tumor that shows an overexpression of ALK.
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://www.streetinsider.com/Corporate+News/Roches+Alecensa+Granted+Accelerated+FDA+Approval+in+Lung+Cancer/11147461.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines